Lyell Immunopharma (LYEL) Stock

Lyell Immunopharma (LYEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that Lynn Seely, MD, Lyell's President & CEO, will participate on a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1 at 11:50 a.m. ET.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that members of its senior management team will present and participate in the following upcoming investor conferences:

For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical trials or a Food and Drug Administration approval to rush a stock into the headlines rapidly.

Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients with relapsed/refractory metastatic or advanced melanoma, NSCLC, and colorectal cancer are expected in 2024. Lyell Immunopharma is advancing a 2nd generation CAR-T known as LYL119 and an IND submission for it is expected in 1st half of 2024. It is also advancing a second-generation TIL.

Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC, and LYL845, a TIL targeting melanoma, NSCLC, and CRC. Lyell's proprietary technologies have shown improved proliferation, functionality, and antitumor efficacy in preclinical trials. However, the company's valuation has decreased, and there are concerns about the ROR1 targeting space.

It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was the outcome of the June Fed meeting.

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 2:00pm PT.